Drugs / GC022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03825731 | Jan → Sep 2019 | B-cell acute lymphoblastic leukemia | Hebei Yanda Ludaopei Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-12-09 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Results Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies gracellbio.com ↗
Dual CAR-19-22 (GC022) shows sound safety profile and effectiveness, with 15/16 evaluable r/r B-ALL patients achieving MRD-CR on Day 28 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-12-09 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies gracellbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03825731 ↗ |
| Modality | Cell therapy | “GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22.” NCT03825731 ↗ |
| Target | CD19 | “GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22.” NCT03825731 ↗ |
| Target | CD22 | “GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22.” NCT03825731 ↗ |